Baihaki, Nurshiba I.

HRN: 00-28-58  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/29/2022
CEFUROXIME 500MG (TAB)
12/29/2022
01/04/2023
PO
1tab
BID
S/p NSVD W/ RMLE
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: